- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cue Biopharma (CUE)
Cue Biopharma stock price live, this page displays NASDAQ CUE stock exchange data. View the CUE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cue Biopharma real time stock price chart below.
What Is the Cue Biopharma Stock Price Today?
The Cue Biopharma stock price today is 0.826.
What Is the Stock Symbol for Cue Biopharma?
The stock symbol for Cue Biopharma is ""CUE.""
What Stock Exchange Does Cue Biopharma Trade On?
Cue Biopharma is listed and trades on the NASDAQ stock exchange.
Is Cue Biopharma a Good Stock to Buy?
Determining whether Cue Biopharma—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CUE quote. (ISIN: US22978P1066)
What Is the Cue Biopharma Stock Price Today?
The Cue Biopharma stock price today is 0.826.
What Is the Stock Symbol for Cue Biopharma?
The stock symbol for Cue Biopharma is ""CUE.""
What Stock Exchange Does Cue Biopharma Trade On?
Cue Biopharma is listed and trades on the NASDAQ stock exchange.
Is Cue Biopharma a Good Stock to Buy?
Determining whether Cue Biopharma—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CUE quote. (ISIN: US22978P1066)
Fair Value
An estimate of a Cue Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.800
0.841
52 wk Range
0.450
1.989
CUE Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CUE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Cue Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.8000.841
52 wk Range
0.4501.989
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CUE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Cue Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
4.000
Upside
+384.26%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
Cue Biopharma Company Profile
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Cue Biopharma SWOT Analysis
Strategic Pivot | Cue Biopharma's shift from oncology to autoimmune diseases reshapes its market position and pipeline, sparking debate on future growth potential |
Financial Outlook | With a $41M cash position and restructuring efforts, Cue Biopharma aims to extend its runway into mid-2025, balancing innovation with fiscal prudence |
Pipeline Promise | Explore Cue's evolving portfolio, including CUE-401 and CUE-501, as it targets autoimmune diseases with novel immunotherapies and potential off-the-shelf alternatives |
Market Dynamics | Analysts project price targets ranging from $2 to $15, reflecting varied perspectives on Cue's strategic shift and competitive positioning in the autoimmune secto |
Cue Biopharma Earnings Call Summary for Q4/2023
- CUE-101 and CUE-102 show promise in cancer treatment, with CUE-101 advancing to Phase 2 study for HPV+ head and neck cancer
- Collaboration revenue of $1.8M for Q4 2023, primarily from Ono Pharmaceuticals partnership; $48.5M cash on hand as of Dec 31, 2023
- Company seeks strategic partnerships to enhance development capacity and capital access for oncology and autoimmune programs
- CUE-401 and CUE-500 series demonstrate potential in restoring immune balance for autoimmune diseases
- Data presentations scheduled for ASCO, including longer follow-up and results from ~35 patients in CUE-101-01 and CUE-102 trials
Last Updated: 09/04/2024, 21:36
Read Full TranscriptCompare CUE to Peers and Sector
Metrics to compare | CUE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCUEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | −1.2x | −0.6x | |
PEG Ratio | −0.04 | −0.05 | 0.00 | |
Price/Book | 3.5x | 1.7x | 2.6x | |
Price / LTM Sales | 7.7x | 8.2x | 3.3x | |
Upside (Analyst Target) | 376.2% | 278.7% | 38.7% | |
Fair Value Upside | Unlock | 28.0% | 5.1% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 4.000
(+384.26% Upside)
Earnings
Latest Release
Aug 12, 2025
EPS / Forecast
-0.09 / -0.14
Revenue / Forecast
2.95M / 1.60M
People Also Watch
FAQ
What Stock Exchange Does Cue Biopharma Trade On?
Cue Biopharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Cue Biopharma?
The stock symbol for Cue Biopharma is "CUE."
What Is the Cue Biopharma Market Cap?
As of today, Cue Biopharma market cap is 63.94M.
What Is Cue Biopharma's Earnings Per Share (TTM)?
The Cue Biopharma EPS (TTM) is -0.53.
When Is the Next Cue Biopharma Earnings Date?
Cue Biopharma will release its next earnings report on 05 Nov 2025.
From a Technical Analysis Perspective, Is CUE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Cue Biopharma Stock Split?
Cue Biopharma has split 0 times.
How Many Employees Does Cue Biopharma Have?
Cue Biopharma has 41 employees.
What is the current trading status of Cue Biopharma (CUE)?
As of 28 Aug 2025, Cue Biopharma (CUE) is trading at a price of 0.83, with a previous close of 0.84. The stock has fluctuated within a day range of 0.80 to 0.84, while its 52-week range spans from 0.45 to 1.99.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.